Changes of platelet activation markers in donor platelets concentrates during the storage after the inactivation of pathogens by amotosalen and ultraviolet A radiation technology

Pathogen inactivation treatment of platelet concentrates improves the transfusion safety. The influence of the pathogen inactivation on the platelet activation remained unclear. The aim of the study was to  evaluate the changes of the platelet activation markers in donor platelets concentrates during the storage after the inactivation of pathogens by amotosalen and ultraviolet A. By flow cytometry CD62P (P-Selectin) and activated GPIIb/IIIa surface expression were estimated with a mouse-anti-human IgG1 CD62-PE  antibodies and mouse-anti-human GPIIb/IIIa-FITC (PAC-1) antibodies. In platelet concentrates during the storage the fraction of the spontaneously activated platelets increased and fraction of the platelets capable of specific activation under the action of the ADP agonist decreased. The pathogen reduction did not  affect the ability of platelets to specific activity, but led to an increase in the fraction of the spontaneously activated platelets. Replacement of plasma with a solution SSP⁺ led to the increase in the proportion of spontaneously activated platelets, but during prolonged storage has contributed to the preservation of the fraction of functionally active platelets.

1. Savchenko V.G., Garmaeva T.Ts., Kulikov S.M., Filatov F.P., Sudarikov A.B., Mikhaylova E.A. The efficacy and safety of transfusion therapy of hematological diseases. Therapeutic archive. Russian journal (Terapevticheskiy arhiv). 2006; 7: 12–18. (in Russian)

2. Vetlesen A., Mirlashari M.R., Torsheim I.A., Kjeldsen-Kragh J. Platelet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions. Transfusion. 2005;45(8):1349–55.

3. Irsch J., Lin L. Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT. Transfus. Med. Hemotherapy.2011; 38 (1): 19–31. doi: 10.1159/000323937.

4. Hechler B., Ohlmann Ph., Chafey Ph., Ravanat C., Eckly A., Maurer E., et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion. 2013; 53(6): 1187–200. doi: 10.1111/j.1537-2995.2012.03923.x.

5. Bashir S., Cookson Ph., Wiltshire M., Hawkins L., Sonoda L., Thomas S., et el. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion. 2013; 53(5): 990–1000.

6. Sandgren P., Diedrich B. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function. Vox Sang. 2015; 108(4): 340–9. doi: 10.1111/vox.12232.

7. Dumont L.J., Larry J., Jose A., Friedman K.D., Vassallo R.R., Whitley P.H., et al. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion. 2013; 53(5): 972–80.

8. Council of Europe. Guide to the preparation, use and Quality – Assurance of Blood Components. Strasbourg: Council of Europe Press; 2013. Available at: www.edqm.eu.

9. Gulliksson H., AuBuchon P., Cardigan R., Van Der Meer F., Murphy S., Prowse C. Storage of platelets in additive solutions: a multicentre study of the in vitro effects of potassium and magnesium. Vox Sang. 2003; 85(3): 199–205. doi: 10.1046/j.1423-0410.2003.00356.x.

10. Gupta A., ChandraT., Kumar A. In vitro function of random donor platelets stored for 7 days in composol platelet additive solution. Asian J. Transfus. Sci. 2011; 5(1): 11–4. doi:10.4103/0973-6247.7569.

11. Azimova M.Kh., Galstyan G.M., Gaponova T.V., Karyakin A.V., Kryukova G.N., Nekhaevskaya S.S., et al.. Biochemical parameters of donor platelet concentrates during the storage after pathogen inactivation with the aid of technology “Amotosalen + ultra-violet A irradiation” in vitro. Hematology and Transfusiology, Russian Journal (Gematologiya i transfusiologiya). 2017; 62(1): 37–40. (in Russian)

12. Decree of the Government of the Russian Federation No 29 of 26 Jan 2010. On approving the technical regulation about safety requirements of blood, its products, blood-substituting solutions and technical means used in transfusioninfusion therapy. (amendments and supplements of 12.10.2010, 4.09.2012). Available at: http://www.consultant.ru/document/cons_doc_LAW_96793/. (accessed 11 Sept 2017) (in Russian)

13. INTERCEPT viruses inactivation claims. Available at: http://www.INTERSEPTbloodsystem.com/resource-center/technicalda-sheets/INTERCEPTblood-system-for-platelets/INTERCEPTviruses.html; http://www.cerus.com; http://www.амотосален+УФА.bloodsystem.com (accessed 11 Sept 2017)

14. Shattil S.J., Hoxie J.A., Cunningham M., Brass L.F. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. Biol. Chem. 1985; 260(20): 11107–14.

15. Seghatchian J. Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers. Transfus. Apher. Sci. 2006; 34(1):125–30. doi: 10.1016/j.transci.2005.09.002

16. Klinger M.H. The storage lesion of platelets: ultrastructural and functional aspects. Ann. Hematol. 1996; 73(3): 103–12.

17. Rinder H.M., Murphy M., Mitchell J.G., Stocks J., Ault K.A., Hillman R.S. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion. 1991; 31(5): 409–14.

18. Johnston G.I., Bliss B.A., Newman P.J., McEver P.J. Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of the adhesion receptors for leukocytes. J. Biol.Chem. 1990; 265(34): 21381–85.

19. Abonnenc M., Sonego G., Crettaz D., Aliotta A., Prudent M., Tissot J.D., Lion N. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVBtreated platelet concentrates. Transfusion. 2015; 55(9): 2219–30. doi: 10.1111/ trf.13123.

20. Rasongles P., Angelini-Tibert M.F., Simon P., Currie C., Isola H., Kientz D., et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de La Reunion. Transfusion. 2009; 49(6): 1083–91.

21. Prowse C.V. Component pathogen inactivation: a critical review. Vox Sang. 2013;104 (3): 183–99. doi: 10.1111/j.1423-0410.2012.01662.x

22. Ringwald J., Zimmermann R., Eckstein R. The new generation of platelet additive solution for storage at 22°С: Development and Current Experience. Transfus. Med. Rev. 2006; 20(2): 158–64. doi: 10.1016/j.tmrv.2005.11.003.

23. de Wildt-Eggen J., Schrijver J., Bins M., Gulliksson H. Storage of platelets in additive solutions:effects of magnesium and/or potassium. Transfusion. 2002; 42(1): 76–80.

24. Karpova O.V., Roitman E.V., Ignatova A.A.., Madzaev S.R., Rumyancev S.A. Plyasunova S.A., Trahtman P.E. Evaluation of the quality of platelet concentrates prepared by apheresis method and stored in additive solution SSP+. Russian Journal Pediatric Hematology/Oncology and Immunopathology (Voprosy gematologii, onkologii i immunopatologii v pediatrii). 2014; 13(2): 20–4. (in Russian)

25. Miyaji R., Sakai M., Urano H., Nakata K., Sakamoto H., Shirahata A. Decreased platelet aggregation of platelet concentrate during storage recovers in the body after transfusion. Transfusion. 2004; 44(6): 891–9.

26. Bikker A., Bouman E., Sebastian S., Korporaal S.J., Urbanus R.T., Fijnheer R., et al. Functional recovery of stored platelets after transfusion. Transfusion. 2016; 56(5): 1030–7. doi: 10.1111/trf.13544.